Trial reportWorld journal of urology2019
The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study.
Trial report in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Complementary therapies in the control of male lower urinary tract symptoms: A systematic review.Revista latino-americana de enfermagem · 2022Pooled it
- The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial.World journal of urology · 2021Trial
- Quantification of the Role of TeupolMedicina (Kaunas, Lithuania) · 2025Observational
- Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms.Prostate cancer and prostatic diseases · 2025Article
- The Novel Histological Prostatic Inflammation Score Helps Defining the Association Between Stromal and Glandular Inflammation with the Risk of Prostate Cancer at Prostate Biopsy.Diagnostics (Basel, Switzerland) · 2025Article
- Advancements in Phytosomal Therapies for Liver Cancer: A Comprehensive Review.Current cancer drug targets · 2025Review
- Role of Phytotherapy in the Management of BPH: A Summary of the Literature.Journal of clinical medicine · 2023Review
- A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia.Journal of clinical medicine · 2023Review
- The Role of Combination Therapy with α-Blockers and Hexanic Extract ofJournal of clinical medicine · 2022Review
- Hexanic Extract of Serenoa repens (PermixonDrugs & aging · 2022Review
- Efficacy and Safety of the Hexanic Extract ofJournal of clinical medicine · 2022Article
- Treatment of Benign Prostatic Hyperplasia by Natural Drugs.Molecules (Basel, Switzerland) · 2021Review
- Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients.Scientific reports · 2021Article
- The Clinical Impact of Hexanic Extract ofJournal of clinical medicine · 2020Article
- Pharmacology of the lower urinary tract: update on LUTS treatment.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effect of hexanic extract of Serenoa repens (HESr) on prostatic inflammation in patients with diagnosed prostatic inflammation.
methodsPatients with prostatic inflammation histologically confirmed by TRUS prostatic biopsy were randomized either to receive HESr (320 mg/day) or no treatment. A second biopsy was performed 6 months later according to standard clinical practice. Inflammation was assessed by the Irani's score and immunohistochemical staining using the CD3, CD4 and CD8 (for T-leucocytes), CD20 (for B-leucocytes) and CD163 (for macrophages) antibodies.
resultsOverall 97 patients were eligible for analysis. In the HESr group the mean inflammation grading and aggressiveness grading score significantly decreased from 1.55 and 1.55 at baseline to 0.79 (p = 0.001) and 0.87 (p = 0.001) at the second biopsy, respectively. In the control group the mean inflammation grading score was 1.44 at first biopsy and 1.23 at the second biopsy. The mean aggressiveness gradings core was 1.09 and 0.89, respectively. No statistical significance was found (p = 0.09 and p = 0.74).The mean decrease in all inflammation scores was statistically higher in the HESr patients compared to controls. The immunohistochemical staining showed a significant change in the expression of the analyzed antibodies for the HESr patients compared to the first biopsy. In the nontreatment group, no significant difference was found at the second biopsy. The change in expression of each antibody in the HESr group was statistical significant compared to control.
conclusionsHESr seems to reduce prostatic inflammation in terms of histological and immunohistochemical parameters in this specific patients population.
Indexed as
Identifiers
30027406What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.